Experience

Giiant Pharma Inc.

• Canada
• Research

• Chief Clinical Officer

  • Jan 2021 - Present

  Giiant Pharma is a new, Montreal based, gastroenterology(GI)-focused company with a gut-restricted, colon-specific PDE4 inhibitor prodrug as lead program, to treat and manage inflammatory bowel diseases (IBD). The Company is also creating a Drug Hunting Club to identify and acquire GI-liver focused assets in order to build a strong franchise in Precision Therapeutics. Giiant Pharma is a new, Montreal based, gastroenterology(GI)-focused company with a gut-restricted, colon-specific PDE4 inhibitor prodrug as lead program, to treat and manage inflammatory bowel diseases (IBD). The Company is also creating a Drug Hunting Club to identify and acquire GI-liver focused assets in order to build a strong franchise in Precision Therapeutics.



Laurent Pharma Inc.

• Chief Development Advisor; co-founder

  • Sep 2013 - Present

  Laurent Pharma develops an innovative form of fenretinide (LAU-7b), a synthetic retinoid which corrects lipidomic imbalance in Cystic Fibrosis(CF) patients and favours inflammation resolution. This technology originates from McGill University and has been first evaluated in a Phase Ib clinical study. The company is currently conducting a large, international Phase 2 adult CF clinical trial (APPLAUD). Laurent also initiated a Phase 2 study in hospitalized COVID-19 patients, in light of the antiviral (host oriented) and anti-inflammatory properties of LAU-7b.



Patrick Colin Consultant Inc.

• President

  • Sep 2007 - Present

  PCC Inc. is a Montreal based consulting firm specialized in drug development, from preclinical to Phase IV clinical. PCC inc. focuses on the strategic aspects of overall drug development programs.Drug development services offered in more than 10 Therapeutic Areas, including Gastroenterology, Cardiology, Metabolic Diseases, Oncology, etc...Strong expertise in GI-liver disease drug development. Experience in conducting international Phase 2 and 3 trials. Experience in clinical research in Eastern Europe, as well as developing countries such as Peru and Dominican Republic.Expertise in Clinical Pharmacology (Phase I SAD and MAD studies, PK, Biosimilar PK profiling, Bioequivalence, etc...)Provides privileged access to a large international Clinical Investigators-KOLs Network, including Poland and other Central and Eastern Europe countries.



Verlyx Pharma Inc.

• Chief Development Officer

  • Mar 2015 - Jan 2018

  Verlyx Pharma was a Montreal, Canada, based clinical stage biotech specialized in the development of innovative products designed to treat inflammatory liver diseases such as Non Alcoholic Steatohepatitis ( NASH) , Acute Alcoholic Hepatitis ) AAH) and other prevalent hepatic disorders. Verlyx Pharma was a Montreal, Canada, based clinical stage biotech specialized in the development of innovative products designed to treat inflammatory liver diseases such as Non Alcoholic Steatohepatitis ( NASH) , Acute Alcoholic Hepatitis ) AAH) and other prevalent hepatic disorders.



Gicare Pharma Inc.

• Canada
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Chief Development Officer, co-founder

  • Jul 2011 - Feb 2015

  Gicare Pharma was a clinical stage Canadian biopharmaceutical firm specialized in the development of innovative, orally administered colonic analgesic drugs designed as an alternative to IV sedation for patients under going full colonoscopy. Gicare Pharma was a clinical stage Canadian biopharmaceutical firm specialized in the development of innovative, orally administered colonic analgesic drugs designed as an alternative to IV sedation for patients under going full colonoscopy.



GInova Pharma

• Canada
• Personal Care Product Manufacturing

• Chief Development Officer, co-founder

  • Jan 2008 - Feb 2010

  GInova was a new biotech founded by 7 former pharma executives ( 3 from Axcan, including myself...). We have been trying to close a Series A round of financing of $ 20 M CDN for the last 18 months. We managed to successfully secured $ 15 M so far ( Term Sheet established with 3 VCs). However, we had to terminate this project, because we could not our reach our $ 20 M objective. The current financial context is extremely challenging, and GInova is now trying to license out its 3 promissing technologies.GInova 's innovative drug technologies address unmet medical needs for Celiac Disease, Ulcerative Colitis , and Sedation for Colonoscopy. As the CDO of the company, I was responsible for all aspects of the drug development programs, from pre-clinical tox to Phase II clinical.



Axcan Pharmaceuticals

• Pharmaceutical Manufacturing

• VP , R & D

  • 1994 - 2006

  This position was responsible for all aspects of Axcan's GI and liver disease drug development programs, including preclinical (CMC and tox), as well as Phase I, II and III clinical development. During my 12 years at Axcan, our team managed to obtain 12 marketing approvals in Canada, USA and EU (NDAs, SNDAs, NDS, etc...)A strong collaboration was also established between R & D and other key departments, such as Marketing, BD and Medical Affairs.R & D efforts at Axcan led to the approval of 12 regulatory filings, between 1994 and 2007 ( NDAs, SNDAs, NDSs, SNDSs, MAs, PMAs)I also actively participated to Axcan 's IPO in 1995, as well as Nasdaq listing in 1999.



Bristol-Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Manager, Metabolism

  • 1992 - 1994

  Responsible for Phase 2 clinical development, in the areas of dyslipidemia and peripheral vascular disease.

• Project Leader

  • May 1989 - May 1992

  Contributed to Phase 1-2 clinical development of pravastatin, a hypocholesterolemic drug.



Squibb Pharmaceuticals

• United States
• Pharmaceutical Manufacturing

• Project Manager

  • May 1987 - May 1989

  Responsible for biopharmaceutical development, therapeutic equivalence clinical studies, and bioanalytical development. Responsible for biopharmaceutical development, therapeutic equivalence clinical studies, and bioanalytical development.